{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:31:26Z","timestamp":1789561886971,"version":"build-2803163510"},"reference-count":73,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82471857"],"award-info":[{"award-number":["82471857"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["91859110"],"award-info":[{"award-number":["91859110"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["2022XD045"],"award-info":[{"award-number":["2022XD045"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"crossref","award":["19XD1420200"],"award-info":[{"award-number":["19XD1420200"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JFB"],"abstract":"<jats:p>Background\/Objectives: Aberrant metabolism in tumors exacerbates the immunosuppressive tumor microenvironment. The immunosuppressive metabolite kynurenine inhibits the activation of effector T cells. Current antitumor drugs targeting kynurenine focus on small molecule inhibitors, which exhibit suboptimal efficacy in suppressing kynurenine generation owing to the diversity of kynurenine synthesis pathways. In contrast, kynureninase (KYNase) can directly metabolize kynurenine regardless of the production source. However, its delivery is hindered by short blood-circulation half-life and poor tumor accumulation. Additionally, photodynamic therapy (PDT) has been reported to synergize with immunotherapy, suggesting a potential combinatorial photodynamic immunometabolic cancer therapy with KYNase. Methods: A KYNase-Fc fusion protein was prepared to prolong blood circulation and enhance tumor accumulation of KYNase. Meanwhile, KYNase-Fc served as a nanocarrier for photosensitizer pheophorbide A (PhA) due to the high binding affinity between KYNase-Fc and PhA. Through self-assembly, KYNase-Fc\/PhA nanoparticles (KYNase-Fc\/PhA NPs) were prepared without extra carrier materials. Results: Compared with the PEGylated KYNase, KYNase-Fc exhibited significantly prolonged blood circulation, enhanced tumor accumulation and effective tumor suppression. Moreover, the prepared KYNase-Fc\/PhA NPs facilitated rapid PhA tumor accumulation. The combined photodynamic immunometabolic therapy alleviated the immunosuppressive microenvironment and significantly inhibited the growth of subcutaneous 4T1 tumors in mice. Conclusions: KYNase-Fc offered a carrier-free nanomedicine for co-delivery of PhA for photodynamic immunometabolic antitumor therapy with enhanced efficacy, providing a promising platform for clinical translation.<\/jats:p>","DOI":"10.3390\/jfb17020094","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:06:59Z","timestamp":1770984419000},"page":"94","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Self-Assembled Nanoparticles with Kynureninase-Fc Fusion Protein and Pheophorbide A for Photodynamic Immunometabolic Cancer Therapy"],"prefix":"10.3390","volume":"17","author":[{"given":"Chen","family":"Zhang","sequence":"first","affiliation":[{"name":"School of Pharmaceutical Sciences, Minhang Hospital, Key Laboratory of Smart Drug Delivery Ministry of Education & State Key Laboratory of Molecular Engineering of Polymers, Fudan University, 826 Zhangheng Road, Shanghai 201203, China"},{"name":"Quzhou Fudan Institute, 108 Minjiang Avenue, Quzhou 324002, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afeng","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Minhang Hospital, Key Laboratory of Smart Drug Delivery Ministry of Education & State Key Laboratory of Molecular Engineering of Polymers, Fudan University, 826 Zhangheng Road, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzheng","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Minhang Hospital, Key Laboratory of Smart Drug Delivery Ministry of Education & State Key Laboratory of Molecular Engineering of Polymers, Fudan University, 826 Zhangheng Road, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Li","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Minhang Hospital, Key Laboratory of Smart Drug Delivery Ministry of Education & State Key Laboratory of Molecular Engineering of Polymers, Fudan University, 826 Zhangheng Road, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1333-0274","authenticated-orcid":false,"given":"Wei","family":"Lu","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Minhang Hospital, Key Laboratory of Smart Drug Delivery Ministry of Education & State Key Laboratory of Molecular Engineering of Polymers, Fudan University, 826 Zhangheng Road, Shanghai 201203, China"},{"name":"Quzhou Fudan Institute, 108 Minjiang Avenue, Quzhou 324002, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1126\/science.359.6382.1344","article-title":"The cancer immunotherapy revolution","volume":"359","author":"Kelly","year":"2018","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1146\/annurev.immunol.021908.132544","article-title":"Immune therapy for cancer","volume":"27","author":"Dougan","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41573-021-00155-y","article-title":"Beyond immune checkpoint blockade: Emerging immunological strategies","volume":"20","author":"Kubli","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2015.10.009","article-title":"Immune suppressive mechanisms in the tumor microenvironment","volume":"39","author":"Munn","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1158\/2326-6066.CIR-20-0791","article-title":"Fueling the revolution: Targeting metabolism to enhance immunotherapy","volume":"9","author":"Leone","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12943-024-01981-5","article-title":"Cancer immunometabolism: Advent, challenges, and perspective","volume":"23","author":"Dang","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/s41556-022-01002-x","article-title":"Metabolic communication in the tumour-immune microenvironment","volume":"24","author":"Kao","year":"2022","journal-title":"Nat. Cell Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41577-024-01026-4","article-title":"Cancer cell metabolism and antitumour immunity","volume":"24","author":"Rathmell","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Oweira, H., Lahdou, I., Mehrle, S., Khajeh, E., Nikbakhsh, R., Ghamarnejad, O., Terness, P., Reissfelder, C., Sadeghi, M., and Ramouz, A. (2022). Kynurenine is the main metabolite of tryptophan degradation by tryptophan 2,3-dioxygenase in HepG2 tumor cells. J. Clin. Med., 11.","DOI":"10.3390\/jcm11164794"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Mor, A., Tankiewicz-Kwedlo, A., and Pawlak, D. (2021). Kynurenines as a novel target for the treatment of malignancies. Pharmaceuticals, 14.","DOI":"10.3390\/ph14070606"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e957994","DOI":"10.4161\/21624011.2014.957994","article-title":"Trial watch: IDO inhibitors in cancer therapy","volume":"3","author":"Vacchelli","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1158\/1078-0432.CCR-16-2272","article-title":"First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 Epacadostat (INCB024360) in patients with advanced solid malignancies","volume":"23","author":"Beatty","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"18490","DOI":"10.1021\/acsami.4c00513","article-title":"Metabolic modulation of kynurenine based on kynureninase-loaded nanoparticle depot overcomes tumor immune evasion in cancer immunotherapy","volume":"16","author":"Chae","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1126\/science.aam7340","article-title":"Waste disposal-an attractive strategy for cancer therapy","volume":"355","author":"Salami","year":"2017","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nbt.4180","article-title":"Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme","volume":"36","author":"Triplett","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1021\/acs.bioconjchem.7b00719","article-title":"Enzymes as immunotherapeutics","volume":"29","author":"Farhadi","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/jssc.202000765","article-title":"Therapeutic Fc-fusion proteins: Current analytical strategies","volume":"44","author":"Duivelshof","year":"2021","journal-title":"J. Sep. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.addr.2015.02.005","article-title":"The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy","volume":"91","author":"Sockolosky","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Li, Z., Xu, J., Lin, H., Yu, S., Sun, J., Zhang, C., Zhang, S., Li, T., Yang, A., and Lu, W. (2025). Interleukin-15Ralpha-sushi-Fc fusion protein co-hitchhikes interleukin-15 and pheophorbide A for cancer photoimmunotherapy. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17050615"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e2101410","DOI":"10.1002\/adma.202101410","article-title":"Second near-infrared light-activatable polymeric nanoantagonist for photothermal immunometabolic cancer therapy","volume":"33","author":"Xu","year":"2021","journal-title":"Adv. Mater."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12943-021-01486-5","article-title":"Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy","volume":"21","author":"Lian","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1021\/acs.chemrev.1c00381","article-title":"Recent strategies to develop innovative photosensitizers for enhanced photodynamic therapy","volume":"121","author":"Pham","year":"2021","journal-title":"Chem. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1016\/j.apsb.2024.07.002","article-title":"Zinc oxide nanoparticles with catalase-like nanozyme activity and near-infrared light response: A combination of effective photodynamic therapy, autophagy, ferroptosis, and antitumor immunity","volume":"14","author":"Wang","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1016\/j.apsb.2025.05.022","article-title":"Polymer-assisted PD-L1 degradation and targeted photodynamic therapy synergize to suppress immunodeficient tumors","volume":"15","author":"Guo","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"123116","DOI":"10.1016\/j.biomaterials.2025.123116","article-title":"Inhibition of PDT-induced PGE2 surge for enhanced photo-immunotherapy","volume":"317","author":"Liu","year":"2025","journal-title":"Biomaterials"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.apsb.2025.02.020","article-title":"siRNA micelleplexes-mediated glutamine metabolism re-engineering for vascular normalization-boosted photo-immunotherapy","volume":"15","author":"Yi","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.2147\/IJN.S388996","article-title":"Combined photodynamic and photothermal therapy and immunotherapy for cancer treatment: A review","volume":"17","author":"Kong","year":"2022","journal-title":"Int. J. Nanomed."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jconrel.2022.09.035","article-title":"Nanoemulsion applications in photodynamic therapy","volume":"351","author":"Moghassemi","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"111099","DOI":"10.1016\/j.msec.2020.111099","article-title":"Multifunctional nanoparticles as photosensitizer delivery carriers for enhanced photodynamic cancer therapy","volume":"115","author":"Zhang","year":"2020","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.addr.2012.06.006","article-title":"Nanotheranostics for personalized medicine","volume":"64","author":"Mura","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.7150\/thno.18861","article-title":"A tumor-pH-responsive supramolecular photosensitizer for activatable photodynamic therapy with minimal in vivo skin phototoxicity","volume":"7","author":"Li","year":"2017","journal-title":"Theranostics"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/toxsci\/kft179","article-title":"Accumulated polymer degradation products as effector molecules in cytotoxicity of polymeric nanoparticles","volume":"136","author":"Singh","year":"2013","journal-title":"Toxicol. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"17024","DOI":"10.1038\/natrevmats.2017.24","article-title":"Rethinking cancer nanotheranostics","volume":"2","author":"Chen","year":"2017","journal-title":"Nat. Rev. Mater."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: Progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kharissova, O.V., Mart\u00ednez, L.M.T., and Kharisov, B.I. (2020). Nanomaterials and nanocomposites: Classification and toxicity. Handbook of Nanomaterials and Nanocomposites for Energy and Environmental Applications, Springer International Publishing.","DOI":"10.1007\/978-3-030-11155-7"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jconrel.2023.02.026","article-title":"An \u201cIgG-hitchhiking\u201d approach for rapid tumor accumulation and clearance of photosensitizers","volume":"356","author":"Lin","year":"2023","journal-title":"J. Control. Release"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"10242","DOI":"10.1021\/acsnano.9b03466","article-title":"High affinity of chlorin e6 to immunoglobulin G for intraoperative fluorescence image-guided cancer photodynamic and checkpoint blockade therapy","volume":"13","author":"Xu","year":"2019","journal-title":"ACS Nano"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jbiosc.2023.12.016","article-title":"Identification and characterization of rabbit scFv antibodies suitable for immuno-affinity separation of recombinant human kynureninase from Escherichia coli cell lysate","volume":"137","author":"Sugimoto","year":"2024","journal-title":"J. Biosci. Bioeng."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Programs Biomed."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e2007247","DOI":"10.1002\/adma.202007247","article-title":"Activatable polymer nanoenzymes for photodynamic immunometabolic cancer therapy","volume":"33","author":"Zeng","year":"2021","journal-title":"Adv. Mater."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41467-025-55876-0","article-title":"CD133+PD-L1+ cancer cells confer resistance to adoptively transferred engineered macrophage-based therapy in melanoma","volume":"16","author":"Xu","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4236\/aim.2012.22019","article-title":"Purification and biochemical characterization of native and pegylated form of L-asparaginase from of Aspergillus terreus and evaluation of its antiproliferative activity","volume":"02","author":"Said","year":"2012","journal-title":"Adv. Microbiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/jps.22054","article-title":"Delivery of therapeutic proteins","volume":"99","author":"Pisal","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2165\/00063030-200620030-00002","article-title":"Monomeric Fc fusions: Impact on pharmacokinetic and biological activity of protein therapeutics","volume":"20","author":"Dumont","year":"2006","journal-title":"BioDrugs"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e2314349121","DOI":"10.1073\/pnas.2314349121","article-title":"In situ formed depot of elastin-like polypeptide-hirudin fusion protein for long-acting antithrombotic therapy","volume":"121","author":"Tian","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.7150\/thno.18099","article-title":"A unique recombinant fluoroprobe targeting activated platelets allows in vivo detection of arterial thrombosis and pulmonary embolism using a novel three-dimensional fluorescence emission computed tomography (FLECT) technology","volume":"7","author":"Lim","year":"2017","journal-title":"Theranostics"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s41467-021-21436-5","article-title":"Capturing functional two-dimensional nanosheets from sandwich-structure vermiculite for cancer theranostics","volume":"12","author":"Ji","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_48","first-page":"1","article-title":"Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy","volume":"16","author":"Zheng","year":"2022","journal-title":"Bioact. Mater."},{"key":"ref_49","first-page":"663","article-title":"A novel cascaded energy conversion system inducing efficient and precise cancer therapy","volume":"20","author":"Kang","year":"2023","journal-title":"Bioact. Mater."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e1901930","DOI":"10.1002\/smll.201901930","article-title":"Preferential tumor accumulation of polyglycerol functionalized nanodiamond conjugated with cyanine dye leading to near-infrared fluorescence in vivo tumor imaging","volume":"15","author":"Yoshino","year":"2019","journal-title":"Small"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1038\/s41401-025-01609-4","article-title":"Programmed sequential nanostructural conversion at nano-bio interface for synergistic cancer phototheranostics","volume":"46","author":"Sun","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1039\/D2BM01846B","article-title":"Analysis of PEG-lipid anchor length on lipid nanoparticle pharmacokinetics and activity in a mouse model of traumatic brain injury","volume":"11","author":"Waggoner","year":"2023","journal-title":"Biomater. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Wubuli, A., Chai, J., Liu, H., Nijat, D., Li, J., Xia, G., Cao, Q., Zhang, S., Huang, W., and Aipire, A. (2024). In vivo pharmacokinetics of Glycyrrhiza uralensis polysaccharides. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1431221"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/s41551-025-01400-0","article-title":"Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody-STING agonist conjugates","volume":"9","author":"Kimmel","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12943-025-02324-8","article-title":"Lymph node macrophage-targeted interferon alpha boosts anticancer immune responses by regulating CD169-positive phenotype of macrophages","volume":"24","author":"Fukuda","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jconrel.2020.02.004","article-title":"CD44-targeted vesicles encapsulating granzyme B as artificial killer cells for potent inhibition of human multiple myeloma in mice","volume":"320","author":"Zhong","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Ponkshe, P., Wang, Y., and Tan, C. (2023). Systemic protein delivery via inhalable liposomes: Formulation and pharmacokinetics. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15071951"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"368","DOI":"10.18433\/J3H88D","article-title":"Pharmacokinetics and biodistribution of human serum albumin-TIMP-2 fusion protein using near-infrared optical imaging","volume":"14","author":"Lee","year":"2011","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jim.2017.07.009","article-title":"Long-term direct visualization of passively transferred fluorophore-conjugated antibodies","volume":"450","author":"Schneider","year":"2017","journal-title":"J. Immunol. Methods"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41563-019-0566-2","article-title":"The entry of nanoparticles into solid tumours","volume":"19","author":"Sindhwani","year":"2020","journal-title":"Nat. Mater."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1002\/anie.200902672","article-title":"Poly(ethylene glycol) in drug delivery: Pros and cons as well as potential alternatives","volume":"49","author":"Knop","year":"2010","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1021\/acs.oprd.3c00428","article-title":"Striving for uniformity: A review on advances and challenges to achieve uniform polyethylene glycol","volume":"28","author":"Bento","year":"2024","journal-title":"Org. Process Res. Dev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/jps.21916","article-title":"Significance of protein binding in pharmacokinetics and pharmacodynamics","volume":"99","author":"Schmidt","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"ref_65","unstructured":"Rowland, M., and Tozer, T.N. (1980). Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications, Lippincott Williams & Wilkins."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"105598","DOI":"10.1016\/j.jddst.2024.105598","article-title":"Pheophorbide a-loaded casein micelle for in vivo drug delivery and efficient photodynamic therapy","volume":"95","author":"Kim","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2174\/092986712799034879","article-title":"The chlorophyll catabolite pheophorbide a as a photosensitizer for the photodynamic therapy","volume":"19","author":"Xodo","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1011-1344(01)00267-6","article-title":"State of the art in the delivery of photosensitizers for photodynamic therapy","volume":"66","author":"Konan","year":"2002","journal-title":"J. Photochem. Photobiol. B"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1039\/c0pp00038h","article-title":"Novel photosensitisers derived from pyropheophorbide-a: Uptake by cells and photodynamic efficiency in vitro","volume":"9","author":"Stamati","year":"2010","journal-title":"Photochem. Photobiol. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"667","DOI":"10.4155\/fmc.09.55","article-title":"Designing photosensitizers for photodynamic therapy: Strategies, challenges and promising developments","volume":"1","author":"Garland","year":"2009","journal-title":"Future Med. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00249-007-0204-9","article-title":"Structural and physico-chemical determinants of the interactions of macrocyclic photosensitizers with cells","volume":"36","author":"Mojzisova","year":"2007","journal-title":"Eur. Biophys. J."},{"key":"ref_72","unstructured":"(2026, February 09). VISUDYNE (Verteporfin). U.S. Food and Drug Administration Website, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021119s022lbl.pdf."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e001926","DOI":"10.1136\/jitc-2020-001926","article-title":"Targeting immunogenic cancer cell death by photodynamic therapy: Past, present and future","volume":"9","author":"Alzeibak","year":"2021","journal-title":"J. Immunother. Cancer"}],"container-title":["Journal of Functional Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-4983\/17\/2\/94\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T05:10:22Z","timestamp":1771391422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-4983\/17\/2\/94"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":73,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jfb17020094"],"URL":"https:\/\/doi.org\/10.3390\/jfb17020094","relation":{},"ISSN":["2079-4983"],"issn-type":[{"value":"2079-4983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]}}}